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Since at least 2004 there has been a focus on data shar-
ing and clinical trial disclosure with the requirements
for protocols to be registered in clinicaltrials.gov and for
subsequent manuscripts of the study results to be ac-
cepted for publication by major journals [1]. However,
sponsors of clinical trials have for many years been
widely criticised for not adhering to these requirements
and failing to disclose clinical trials in a timely fashion
(e.g., www.alltrials.net].
In 2013 the European and US pharmaceutical trade
bodies EPFIA/PhRMA published their Principles for re-
sponsible sharing of clinical trial data [2]. This was a
voluntary but significant commitment to clinical trial
transparency and it has led to a significant change in at-
titudes and behaviours towards sharing of clinical trial
data. Many companies have developed processes for
clinical trial data access schemes [3], aligned to the new
EU Clinical Trials Regulation 536/2014 [4] and the
European Medicines Agency’s transparency policies: Ac-
cess to Documents (Policy 0043) [5] and Publications
and Publication of clinical-trial data for medicinal prod-
ucts for human use (Policy 0070) [6]. Whilst there are
common elements to these access schemes, there are
many differences in terms of what existing clinical trial
data are in scope for sharing between companies, ran-
ging from all existing data are considered (no time
limits) versus data available from 2015.
EFPIA recently reported that “According to the
European Medicines Agency around 4000 trials are
authorised each year across the European Economic
Area” [7]. There is a wealth of clinical data being
generated annually and the efforts by Industry and
other data owners, coupled with changes in regula-
tions, now enables medical researchers to seek access
to a large number of sources of patient level data to
support their medical research.
The European Federation of Statisticians in the
Pharmaceutical Industry (EFSPI) issued a paper “Position
on Access to Clinical Trial Data” in 2013 [8]. In this
paper, EFSPI noted its support for responsible data
sharing and highlighted a number of important aspects:
ensuring that credible and robust research is conducted
on any data shared; care is taken to avoid the misuse of
data; there is confirmation that the original informed
consent allows the data to be used in the proposed fur-
ther research; and patient confidentiality is protected.
However, EFSPI also recognized that further guidance
and discussion on key principles and recommendations
for efficient and effective sharing of individual patient
data is needed. Therefore, EFSPI together with the UK
based PSI (Statisticians in the Pharmaceutical Industry)
initiated a working group to look deeper into the chal-
lenges of sharing individual patient data. The result of
this effort has led to the development of four papers
described below.
It is important to recognize that there can be signifi-
cant challenges to working with existing patient level
data sets, for example, data standards have evolved over
time with different data owners following different defi-
nitions and formats. Different approaches for document-
ing and describing these standards have also been used.
Whilst this is not unsurmountable, careful planning and
handling of shared data is required to ensure data are
correctly used in further analyses. Whilst it may be com-
mon in some research settings to share data between insti-
tutions, e.g., MRC have shared data between clinical trial
units for some time [9] and processes and systems to do
this effectively have thus been established, for other data
owners sharing data is a relatively new concept.
Specific regulations and requirements exist to protect
patient confidentiality of any data shared [10], and these
must be followed to ensure data owners appropriately
de-identify and anonymise data. There are significant
concerns by some data holders regarding the potential
for shared de-identified data to be re-identified despite
having legally binding data sharing agreements in place
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to avoid this. To date, published case studies suggest this
practice has generally focused on the linkage of patient
information between large existing health related data-
bases rather than clinical trial data sources. Given the
use of specific informed consents used by patients in
clinical trials that protect their confidentiality and identity,
it is thus not surprising to see data owners being conser-
vative in ensuring data are appropriately de-identified
whilst maintaining as much data utility as possible. How-
ever, whilst there is alignment between some data owners
on minimum expectations relating to de-identification,
there is not yet full agreement on best practices.
Furthermore, there are important technical aspects to
be considered relating to the re-analysis and/or supple-
mental analyses of shared data, such as what constitutes
appropriate interpretation of results from re-analyses
where different methods have been utilized; and poten-
tial over-interpretation, for example, of additional sub-
groups analysed. Finally, the increasing number of data
sharing policies, processes and expertise required to
manage requests for shared data is impacting the role
of statisticians: not only does this bring challenges but it
also provides a number of opportunities that statisticians
can and should embrace. For example, further analysis of
shared data will often result with new medical insights,
and will often enable new clinical questions to be ex-
plored. Together this could influence and shape the roles
and responsibilities of statisticians involved in designing,
analyzing and reporting clinical trials in the future.
A substantial amount of individual patient data from
pharmaceutical clinical development is now being made
available through increased data sharing efforts de-
scribed above. In order to make this effort really feasible
and useful it is important for all data owners to adhere
to data standards, for example CDISC, and to adhere to
clinical trial principles defined in regulatory guidelines
from ICH, for example Statistical Principles in Clinical
Trials (ICH E9). In particular it will be essential for data
owners to be transparent on how results were derived
from study data such that other researchers have a
chance to understand the original analyses to ensure ap-
propriate interpretation of the results of their further
analyses. This is not only a requirement for Industry but
should also be followed by academia and other groups
generating and maintaining clinical data. However, the
analysis of shared data is complex as data standards and
methods for analyses evolve over time, some inconsisten-
cies are likely to occur when shared data are re-analysed.
Where inconsistencies are found, understanding the rea-
sons will be essential to maintain adequate data interpret-
ation. For example, differences between results presented
from a re-analysis when compared to results reported in a
clinical study report (or in a publication of the study, or in
the regulatory approval of the medicine) could be due to
different data cuts, different analysis requirements, or dif-
ferent analysis populations. Often trying to rationalize
these differences will be difficult as the available documen-
tation may be limited in terms of describing all the steps
of the analyses.
The EFSPI/PSI Data Sharing Working Group, which in-
cludes Industry and academic representatives, has devel-
oped a series of 4 papers that focus on these key topics:
(1) (Sudlow et al: A primer for researchers working with
patient level data sets, submitted), (2) (Tucker et al: Ensur-
ing patient confidentiality when sharing patient-level data
from clinical trials, submitted), (3) (Holis et al: Best prac-
tices for analysis of shared clinical trial data, submitted),
and (4) (Manamley et al: Does data sharing change the
role of statisticians?, submitted). All four papers discuss
and debate a wide range of aspects for sharing data. This
first paper discusses on the importance of researchers pro-
viding a through list of requirements seeking access to
shared data to ensure that their proposed research can be
fulfilled. The second paper provides an overview and rec-
ommendations for data owners on acceptable criteria for
anonymization of shared data. While the mechanics of
this will be most relevant to industry providers of shared
data, it is important for users of these shared data to
understand what measures may have been taken to
anonymize data, and the potential impact of these on their
analyses of the shared data. The third paper discusses the
role of the analysis plan, and what are minimal criteria
that need to be fulfilled in order to make a research plan
meaningful. The analysis plan is considered not only a ne-
cessary condition to get access to individual patient data
but an essential part of the research, and will impact the
interpretation of results obtained. Finally, data sharing will
very likely change the way industry and academia collab-
orate in the future. This may impact also on the abilities
and proficiencies statisticians need to demonstrate to be
successful in the future. This is discussed in the last paper.
There are some topics that have not been addressed in
these papers. One topic concerns data sharing within
industry. Whereas in academia there may be more open
willingness to share data between institutions, due to is-
sues relating to intellectual property rights, sharing data
across companies is more challenging. To do this well, it
would be beneficial if agreements could be achieved on
principles for data sharing within Industry, for example,
that any data shared is used for the stated scientific pur-
poses only and it is not used to inform or fuel marketing
strategies. There is clearly a scientific need for data
sharing within industry, for example to improve study
planning, and more accurately identify patients who
have a high unmet medical need. Whilst statisticians can
and should contribute to discussions relating to princi-
ples for sharing data between companies, they are un-
likely to be the final decision makers. Another topic of
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interest concerns whether all data owners will eventually
agree to a single framework and process for sharing
data, if this is indeed even feasible. Whilst a number of
technical solutions are in development, these are too
new to explore at this time. In addition, there are an in-
creasingly large number of consortiums being formed to
develop shared data networks for specific disease areas
and the impact this could have in future medical re-
search. Finally, there is significant change in how clinical
trial data are being captured with new digital technolo-
gies being utilized to collect source patient data. These
new technologies will likely contribute to the ongoing
transformation underway in how clinical trials are con-
ducted, including how this data would become accessible
for further research.
In summary, we can reasonable expect that broad and
open data sharing as agreed today by pharmaceutical indus-
try will have an impact on drug development and the infor-
mation available to medical and patient communities. It is
important that researchers in academia as well as in indus-
try appreciate the new paradigm shift in data transparency
and the new conditions this brings. This is particularly true
for statisticians as they will remain deeply involved in data
sharing, not just in providing data but also in synthesizing
information from their own analyses and with those
received from independent external researchers.
We acknowledge and thank those members of EFSPI
and PSI who have contributed to the discussions and par-
ticipating in the review of the data sharing publications.
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